Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Seclidemstat mesylate by Salarius Pharmaceuticals for Chronic Myelomonocytic Leukemia (CMML): Likelihood of Approval
Seclidemstat mesylate is under clinical development by Salarius Pharmaceuticals and currently in Phase II for Chronic Myelomonocytic Leukemia (CMML). According...
Data Insights
Seclidemstat mesylate by Salarius Pharmaceuticals for Myelodysplastic Syndrome: Likelihood of Approval
Seclidemstat mesylate is under clinical development by Salarius Pharmaceuticals and currently in Phase II for Myelodysplastic Syndrome. According to GlobalData,...